ABL1 and acute lymphoblastic leukemia: The inhibition of BCR‐ABL activity by imatinib in human ph+ALL cells reduces the prolyl isomerase activity of Pin 1, further suggesting a key role of the newly identified BCR‐ABL‐Pin 1 axis in ph+ALL progression.